Skip to main content
. 2018 Jan 25;175(5):743–762. doi: 10.1111/bph.14099

Table 1.

Haematological and bone marrow values after Epo‐LFM‐A13‐therapy

DLD‐1 xenografts HT‐29 xenografts
Con Epo + LFM Con Epo + LFM
WBC (103 mm−3) 1.8 (1.4–2.2) 2.2 (1.8–4)* 3.5 (2.4–6) 3.3 (2.3–5.3)
RBC (106 mm−3) 8.9 (8.29–9.61) 11.4 (11–12.2)* 8.43 (8.17–11.7) 10.7 (8.6–12.7)*
HGB (g·L−1) 149 (142–157) 205 (163–212)* 150 (143–212) 190 (151–204)*
HCT (%) 45.1 ± 2.98 65.0 ± 2.39* 42 ± 0.69 56.9 ± 7.1*
PLT (103 mm−3) 890.7 ± 57.1 746.0 ± 73.6* 782.4 ± 127.1 702.9 ± 30.7
MCV (μm3) 50 (50–53) 56.5 (54–58)* 50.5 (48–53) 53.5 (50–57)*
MCH (pg) 17 ± 0.31 17.8 ± 0.6* 17.5 ± 0.65 17.5 ± 0.85
MCHC (g·L−1) 316 (308–320) 340 (322–345)* 324 (319–348) 351 (319–358)
Proerythroblasts (%) 0.6 (0–2.2) 1.5 (0.4–3.6) 2.3 (1–4) 2.4 (1–3.4)
Basophilic erythroblast (%) 6.6 (4–10.2) 5.2 (2.6–8.2) 5 (4–7.4) 1.8 (0.8–4)* , #
Polychromatic erythroblast (%) 6.4 (4.2–8.6) 6.1 (2.2–9.4) 9 (5.4–12) 6 (4–8)
Orthochromatic erythroblast (%) 2.8 (2–3.2) 1.4 (0.4–3) 5.4 (4.4–8) 4.4 (4–5.4)#
Myeloblast (%) 0.2 (0–1.6) 0.2 (0–2) 0.3 (0–1.2) 1 (0.6–1.6)
Promyelocyte (%) 1.6 (1.4–3.2) 3.8 (2.4–5)* 4.3 (3.4–9) 3.4 (1.2–6)
Neutrophilic myelocyte (%) 19.2 (14.2–22.2) 23.6 (21.4–25.2) 19.2 (18.2–19.6) 22.4 (19.4–24.2)*
Neutrophilic metamyelocyte (%) 18.4 (15.4–19.8) 19.4 (17–21) 14.8 (11.6–16.4) 16.6 (12.4–21.6)
Neutrophilic band (%) 15 (14.6–20.6) 17.7 (15.2–19.4) 15.7 (14.8–17.6) 15.6 (13.2–18)
Neutrophil segmend (%) 17 (7.8–30.8) 14 (8.8–19) 16.4 (13.2–19.4) 15.2 (13–18.4)
Megacariocyte (%) 0.6 (0.4–1) 1.3 (0.4–2.4) 1.3 (0.6–2.4) 1 (0.4–2.6)
Lymphocyte (%) 3.8 (3.2–4) 2.9 (2–4) 2 (1.4–2.6) 2.8 (1.4–5.8)
Monocyte (%) 0.4 (0.2–0.4) 1.2 (0–1.8) 0.8 (0.4–1.2) 1.2 (0–2.4)

The results are presented as mean values ± SD or median (minimum – maximum), n = 7–8;

*

P < 0.05 (vs. Con),

#

P < 0.05 (DLD‐1 vs. HT‐29).